Explore

Rapid Read Rapid Read
Cleveland Clinic's Innovative Treatment Offers Hope for Terminal Cancer Patient

Cleveland Clinic's Innovative Treatment Offers Hope for Terminal Cancer Patient

Maralee Lellio, diagnosed with Stage IV breast cancer that metastasized to her brain, has experienced a remarkable turnaround in her prognosis thanks to a cutting-edge treatment at the Cleveland Clinic. Initially given a dire prognosis, Lellio's condition improved significantly after being treated with a PARP inhibitor, a medication effective for cancers with genetic mutations like her BRCA-1 positive cancer. Under the care of Dr. Halle Moore, Lellio's brain tumor shrank significantly, and she remained free of active cancer for two years. This treatment has allowed her to pursue her dream of expanding her family, culminating in the birth of her second daughter in July 2024.
Rapid Read Rapid Read
FDA's Project Optimus Drives Dose Optimisation in Oncology Trials

FDA's Project Optimus Drives Dose Optimisation in Oncology Trials

The FDA's Project Optimus, launched in 2021, continues to influence oncology trial designs, as discussed at the AACR 2026. The initiative aims to refine dose selection in cancer treatments, moving away from the traditional maximum tolerated dose approach. Instead, it emphasizes selecting doses based on efficacy, safety, and tolerability. This shift is crucial for newer cancer therapies like targeted treatments and immunotherapies, where the effective dose may be lower than the toxicity threshold. The project encourages more structured, comparative evidence generation in early-phase trials, integrating patient-reported outcomes to better reflect patient experiences and improve treatment tolerability.
Rapid Read Rapid Read
FDA Approval of Gleevec Revolutionizes Cancer Treatment for Chronic Myeloid Leukemia Patients

FDA Approval of Gleevec Revolutionizes Cancer Treatment for Chronic Myeloid Leukemia Patients

Gleevec, a drug approved by the Food and Drug Administration (FDA) 25 years ago, has significantly transformed the treatment of chronic myeloid leukemia (CML). Initially developed by oncologist Brian Druker and biochemist Nicholas Lydon, Gleevec targets the Philadelphia chromosome, a genetic abnormality responsible for the uncontrolled growth of white blood cells in CML patients. The drug, known scientifically as imatinib, was part of a new wave of targeted cancer therapies that aimed to inhibit specific enzymes responsible for cancer cell proliferation. Mel Mann, an Army major diagnosed with CML in 1995, participated in clinical trials for Gleevec and experienced a remarkable recovery, allowing him to live beyond the initial prognosis. The success of Gleevec in clinical trials marked a pivotal shift in cancer treatment, moving away from traditional chemotherapy to more precise, targeted therapies.
Rapid Read Rapid Read
CAR T-Cell Therapy: A Promising Advancement in Cancer Treatment

CAR T-Cell Therapy: A Promising Advancement in Cancer Treatment

CAR T-cell therapy, an innovative cancer treatment, is gaining attention for its potential to enhance the body's immune system to fight cancer. This therapy involves genetically engineering a patient's T-cells to target specific cancer proteins, offering a more precise treatment compared to traditional chemotherapy. The therapy has shown significant success in treating blood cancers, with the potential to prevent relapse by maintaining a protective effect. Researchers are now exploring its application for solid tumors, which present more challenges due to their complex structure. The therapy's development is seen as a major advancement in cancer treatment, with ongoing research aimed at improving its efficacy and reducing costs.
Rapid Read Rapid Read
PHERGain Studies Highlight New Approaches in Breast Cancer Treatment

PHERGain Studies Highlight New Approaches in Breast Cancer Treatment

MEDSIR has presented findings from the PHERGain and PHERGain-2 studies at the ESMO Breast 2026 congress, focusing on de-escalation strategies in HER2-positive early breast cancer. These studies explore the potential for some patients to avoid chemotherapy by using targeted therapies, achieving high disease-free survival rates. The research emphasizes a personalized approach to treatment, aiming to reduce toxicity and improve quality of life for patients.
Rapid Read Rapid Read
PHERGain and PHERGain-2 Studies Highlight Chemotherapy-Free Treatment for Early HER2-Positive Breast Cancer

PHERGain and PHERGain-2 Studies Highlight Chemotherapy-Free Treatment for Early HER2-Positive Breast Cancer

The PHERGain and PHERGain-2 studies, presented at the ESMO Breast 2026 scientific congress, have demonstrated promising results in the treatment of early HER2-positive breast cancer. These studies focus on therapeutic de-escalation strategies that allow certain patients to avoid chemotherapy while maintaining high disease-free survival rates. The PHERGain study, involving 356 patients across Europe, showed that nearly 30% of patients could be treated without chemotherapy, achieving a five-year disease-free survival rate close to 90%. The PHERGain-2 trial, which included 396 patients, reported a 60% pathological complete response rate without initial chemotherapy. These findings suggest that targeted therapies, such as trastuzumab and pertuzumab, can effectively manage the disease while reducing treatment-related toxicity.
Trendline Trendline
enGene Reports Promising Interim Results for Bladder Cancer Gene Therapy Trial

enGene Reports Promising Interim Results for Bladder Cancer Gene Therapy Trial

enGene Reports Promising Interim Results for Bladder Cancer Gene Therapy Trial
Rapid Read Rapid Read
Delphi Diagnostics Validates New Breast Cancer Prognostic Tool in European Journal of Cancer

Delphi Diagnostics Validates New Breast Cancer Prognostic Tool in European Journal of Cancer

Delphi Diagnostics has announced the publication of new clinical data in the European Journal of Cancer, validating the Endocrine Activity Index Recurrence Risk (EAI RR) as a significant independent predictor of outcomes in patients with hormone receptor-positive, node-positive breast cancer. The study analyzed 659 patient samples from the PACS-01 clinical trial, demonstrating that EAI RR provides meaningful prognostic and endocrine-predictive information beyond the 21-gene Recurrence Score. The findings confirm that EAI RR adds statistically significant prognostic information to the Recurrence Score, establishing level 1B evidence. The study included premenopausal women and patients with four or more positive lymph nodes, confirming the prognostic value of EAI/EAI RR in these groups. The EAI strongly predicted benefit from adjuvant endocrine therapy, highlighting its potential to personalize treatment selection for breast cancer patients.
Trendline Trendline
KUBTEC Scientific Launches XCELL TomoRad System to Enhance Cancer Research

KUBTEC Scientific Launches XCELL TomoRad System to Enhance Cancer Research

KUBTEC Scientific Launches XCELL TomoRad System to Enhance Cancer Research
Trendline Trendline
Immunai Expands Collaboration with AstraZeneca in $37.5 Million Deal

Immunai Expands Collaboration with AstraZeneca in $37.5 Million Deal

Immunai Expands Collaboration with AstraZeneca in $37.5 Million Deal
Trendline Trendline
Immunai Expands Collaboration with AstraZeneca in $37.5 Million Deal for Oncology Development

Immunai Expands Collaboration with AstraZeneca in $37.5 Million Deal for Oncology Development

Immunai Expands Collaboration with AstraZeneca in $37.5 Million Deal for Oncology Development
Trendline Trendline
Exelixis to Webcast Fireside Chats at Upcoming Investor Conferences in May 2026

Exelixis to Webcast Fireside Chats at Upcoming Investor Conferences in May 2026

Exelixis to Webcast Fireside Chats at Upcoming Investor Conferences in May 2026